释 义 n. 阿柏西普（药名）
例 句 To compare the efficacy and safety of brolucizumab with aflibercept to treat neovascular age-related macular degeneration (AMD). Brolucizumab与阿帕西普治疗新生血管性年龄相关性黄斑变性（AMD）的疗效和安全性比较。
玻璃体内注射Aflibercept + 抗血小板衍生生长因子受体 β 治疗nAMD: 2期CAPELLA试验的结果
作者： Jeffrey S. Heier
METHODS: Patients were randomized 1:2:2 to low-dose combination intravitreal anti-PDGFRβ 1 mg and aflibercept 2 mg (LD combo), high-dose combination intravitreal anti-PDGFRβ 3 mg and aflibercept 2 mg (HD combo), or IAI alone every 4 weeks through week 12. At week 12, patients in the HD combo and IAI groups were re-randomized to continue as assigned or switch to HD combo → IAI or IAI → HD combo and dosed every 4 weeks through week 28. During weeks 28 to 52, patients received treatment as needed per prespecified criteria. This report presents efficacy through week 28 and safety through week 52.